308G/A and 238G/A polymorphisms in the TNF-α gene may not contribute to the risk of arthritis among Turkish psoriatic patients
暂无分享,去创建一个
O. Ozdemır | F. Sılan | S. Işık | Z. Ogretmen | S. Kılıç | M. M. Hız | Meliha Merve Hız
[1] E. Donadi,et al. HLA‐C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients , 2016, International journal of dermatology.
[2] Xiaoming Liu,et al. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis. , 2015, International immunopharmacology.
[3] C. Salvarani,et al. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis , 2015, The Journal of Rheumatology. Supplement.
[4] A. Roussaki-Schulze,et al. Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques. , 2015, Experimental and therapeutic medicine.
[5] C. De Simone,et al. TNF‐alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] A. Barton,et al. Identifying a novel locus for psoriatic arthritis , 2015, Rheumatology.
[7] T. Gheita,et al. Clinical significance of serum TNFα and -308 G/A promoter polymorphism in rheumatoid arthritis , 2015 .
[8] M. Suárez-Fariñas,et al. Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis , 2015, Arthritis & rheumatology.
[9] V. Trajković,et al. TNF, IL12B, and IFNG Gene Polymorphisms in Serbian Patients with Psoriasis , 2015, Annals of dermatology.
[10] P. Mandich,et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. , 2014, The Journal of investigative dermatology.
[11] R. Mössner,et al. Complex role of TNF variants in psoriatic arthritis and treatment response to anti-TNF therapy: evidence and concepts. , 2014, The Journal of investigative dermatology.
[12] H. Hussein,et al. Serum tumor necrosis factor alpha (TNF-α) level in patients with Behçet’s disease: Relation to clinical manifestations and disease activity , 2014 .
[13] D. Cai,et al. Associations between Tumor Necrosis Factor-α Polymorphisms and Risk of Psoriasis: A Meta-Analysis , 2013, PloS one.
[14] Juan Li,et al. Single Nucleotide Polymorphisms in the Tumor Necrosis Factor-Alpha Gene Promoter Region Alter the Risk of Psoriasis Vulgaris and Psoriatic Arthritis: A Meta-Analysis , 2013, PloS one.
[15] T. Gheita,et al. Clinical significance of serum TNFα and -308 G/A promoter polymorphism and serum Il-6 and -174 G/C promoter polymorphism in systemic lupus erythematosus patients , 2012 .
[16] S. Ibrahim,et al. Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis , 2012 .
[17] M. Lebwohl,et al. Potential complications associated with the use of biologic agents for psoriasis. , 2007, Dermatologic clinics.
[18] Dafna Gladman,et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.
[19] D. Gladman,et al. TNFα polymorphisms and risk of psoriatic arthritis , 2005 .
[20] R. Stern,et al. Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.
[21] E. Berardesca,et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis , 2005, The British journal of dermatology.
[22] B. Bresnihan,et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. , 2003, Arthritis and rheumatism.
[23] J. Kalden,et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. , 2002, Arthritis and rheumatism.
[24] C. López-Larrea,et al. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. , 2002, The Journal of rheumatology.
[25] A. Cambon-Thomsen,et al. Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. A. El-Rahman,et al. Ultrasonographic evaluation of lower limb enthesis in patients with early spondyloarthropathies , 2013 .
[27] I. König,et al. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. , 2005, The Journal of investigative dermatology.
[28] S. D'alfonso,et al. A polymorphic variation in a putative regulation box of the TNFA promoter region , 2004, Immunogenetics.
[29] T Fredriksson,et al. Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.